5th Mar 2009 10:44
BEXIMCO PHARMACEUTICALS LTD.
|
News Release |
March 5 2009 |
SEC Consent to GEM Placing
Further to the announcement of 19 February 2009, Beximco announces that the Securities and Exchange Commission has accorded its consent under the provisions of the Securities and Exchange Commission (Issue of Capital) Rules 2001, for the issuance of 16,000,000 Ordinary Shares of Tk 10 each at an issue price up to Tk 312.50 per share (including a premium up to Tk 302.50 per share) and Warrants to subscribe for a maximum 2,500,000 Ordinary Shares of Tk 10 each at an issue price at Tk 200 per share (including a premium of Tk 190 per share), through a private placement with GEM Global Yield Fund Limited.
For further enquiries please contact:
Libertas Capital
Aamir Quraishi / Anthony Rowland
Tel: +44 (0)20 7569 9650
Financial Dynamics
David Yates / Susan Quigley
Tel: +44 (0)20 7269 7169
Notes to Editors
About Beximco Pharmaceuticals Limited
Founded in 1976 and based in Dhaka, Bangladesh, BPL manufactures and sells generic pharmaceutical formulation products, active pharmaceutical ingredients and intravenous fluids. The Company also manufactures and markets its own branded generics for almost all diseases. The Company also undertakes contract manufacturing for multinational pharmaceutical companies. The Company operates from a 20 acre site in Dhaka and currently employs over 2,400 staff.
The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and in other markets overseas, principally in East Africa, Pacific Island and Central American countries and South East Asia, including Singapore and Hong Kong.
Related Shares:
Beximco Pharma